X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
REGN1979 (odronextamab) is a novel, off-the-shelf, CD20×CD3 bispecific antibody, which is being evaluated for the treatment of relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma.
Lead Product(s): Odronextamab,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: REGN1979
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
L19TNF (onfekafusp alfa) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. It is being evaluated in combination with doxorubicin for the treatment of first-line advanced or metastatic soft tissue sarcoma.
Lead Product(s): Onfekafusp Alfa,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: L19TNF
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
The collaboration aims to help evaluate therapeutic response and provide molecular insights for Rutgers Cancer Institute trial examining early-stage triple-negative breast cancer patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.
Lead Product(s): Doxorubicin Hydrochloride,Carboplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rutgers Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2023
Details:
REGN1979 (odronextamab) is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. It is being investigated for relapsed/refractory diffuse large B-cell lymphoma.
Lead Product(s): Odronextamab,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: REGN1979
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2023
Details:
Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Through the collaboration, Shasqi will apply its novel tumor-targeted Click Activated Protodrugs Against Cancer (CAPAC®) platform to the development of new cancer therapies and research on Shasqi's intratumorally injected biopolymer, SQ3370 (SQL70).
Lead Product(s): SQL70,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 04, 2023
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Keytruda (pembrolizumab), a humanized mAb, anti-PD-1 therapy that blocks the interaction between PD-1 and its ligands, is being developed in combination with chemotherapy in patients with high-risk, early-stage ER+/HER2- breast cancer.
Lead Product(s): Pembrolizumab,Paclitaxel,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Details:
Under the agreement, Cantex gets exclusive worldwide license for intellectual property related to the potential use of TTP488 (azeliragon), a small molecule RAGE inhibitor, to treat, prevent or alleviate cancer treatment-related cognitive decline.
Lead Product(s): Azeliragon,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Neurology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 16, 2023
Details:
The Company intends to use net proceeds for its IMX-110 plus tislelizumab Phase 1b combination clinical trial and its IMX-110 monotherapy clinical trial. IMX-110 is a potential first-line therapy for soft tissue sarcoma.
Lead Product(s): Doxorubicin Hydrochloride,Tislelizumab
Therapeutic Area: Oncology Product Name: IMX-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bridgewest Group
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 14, 2023
Details:
Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, MMAE, utilizing Seagen's proprietary technology,for the treatment of Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
HF158K1, a drug encapsulated immunoliposome containing doxorubicin, which being investigated forbsolid tumors include breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterus and cervix cancers with HER2 low and HER2+ expression.
Lead Product(s): Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: HF158K1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Early-Stage Classical Hodgkin Lymphoma.
Lead Product(s): Brentuximab Vedotin,Nivolumab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
LB-100 is an inhibitor of PP2A, added to doxorubicin significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for advanced soft tissue sarcoma.
Lead Product(s): LB-100,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
Through the collaboration, Shasqi will apply its novel tumor-targeted CAPAC® platform to the development of new cancer therapies and will focus on Shasqi’s SQ3370, consisting of SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin.
Lead Product(s): SQL70,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: SQ3370
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Enterprise Innovation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2023
Details:
ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with liposomal doxorubicin and KEYTRUDA® (pembrolizumab), in patients with recurrent platinum-resistant ovarian cancer.
Lead Product(s): Evorpacept,Pembrolizumab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
LB-100 is an inhibitor of PP2A, added to doxorubicin significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells. It is being investegated for advanced soft tissue sarcoma.
Lead Product(s): LB-100,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LB-100
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
LY3012207 (olaratumab) is a mAb targeting PDGFRα. It was granted accelerated approval in the U.S. and conditional approval in the EU based on Phase II trial data which showed a 1-year survival benefit in patients with STS, when given in combination with standard chemotherapy.
Lead Product(s): Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LY3012207
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Telix Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
The gross proceeds will be used to finance and further support the company’s ongoing Phase 2 clinical study evaluating its CD40 antibody, APX005M (sotigalimab), in combination with doxorubicin in patients with liposarcoma.
Lead Product(s): Sotigalimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Brookline Capital Markets
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 24, 2023
Details:
ADCETRIS (brentuximab vedotin), is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of cHL and expressed on the surface of several types of lymphomas. It is approved in seven indications in the U.S.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
The results show that trilaciclib monotherapy can improve the ratio of CD8+ T cells to Tregs and thus may enhance the overall antitumor immune response and confirm the trends we observed in preclinical studies and in peripheral blood in our Phase 2 trial in TNBC.
Lead Product(s): Trilaciclib,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
YH001 is an IgG1 antibody against CTLA-4 that has shown enhanced antibody dependent cellular cytotoxicity and complement dependent cytotoxicity in vitro. YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared to ipilimumab.
Lead Product(s): YH001,Envafolimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: YH001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
APX005M (sotigalimab) is a CD40 agonist that has been designed to reverse the systemic immune suppression that typically affects cancer patients, through the activation of several mechanisms of immune functionality.
Lead Product(s): Sotigalimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary technology.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Vincristine Sulfate
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Zepzelca (lurbinectedin) is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of cell cycle.
Lead Product(s): Lurbinectedin,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
YH001 is an IgG1 antibody targeting CTLA-4,has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab.
Lead Product(s): YH001,Envafolimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: YH001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: TRACON Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
YH001, an IgG1 antibody against CTLA-4 invented by Biocytogen, the parent company of Eucure Biopharma, and licensed by TRACON, has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro.
Lead Product(s): YH001,Envafolimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: YH001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutated breast cancer.
Lead Product(s): ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Tirapazamine (TPZ) with conventional trans-arterial chemoembolization had a good safety profile and promising efficacy signals in early- and intermediate-stage liver cancer, including in patients who had progression or recurrence after standard therapy.
Lead Product(s): Tirapazamine,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The trial showed ADCETRIS (brentuximab vedotin) in combination with standard of care dose-intensive chemotherapy AVE-PC achieved superior event-free survival (EFS) compared to the current standard of care for the pediatric dose-intensive regimen of ABVE-PC.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
ADCETRIS (Brentuximab Vedotin), is indicated for the treatment of adult patients with untreated Stage III/IV classical Hodgkin lymphoma in combination with AVD in the U.S and for the treatment of adult patients with previously untreated CD30-positive Stage IV Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary technology.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
One cycle of IMX-110 (curcumin) produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug).
Lead Product(s): Curcumin,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: IMX-110
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Details:
Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities.
Lead Product(s): ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Groundbreaking overall survival data for Stage III/IV Hodgkin lymphoma patients who were treated with ADCETRIS® (brentuximab vedotin) as part of a first-line therapy combination will be detailed in one of three oral presentations for the antibody-drug conjugate medicine.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
The exclusive worldwide licence will allow Telix to repurpose LY3012207 (olaratumab) as a targeting agent for radiopharmaceutical imaging and therapy of cancer.
Lead Product(s): Olaratumab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: LY3012207
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $230.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement April 10, 2022
Details:
mAbxience has developed and manufactured biological drugs, with commercialized biosimilar product Novex® (Rituximab), through its in-house biosimilars programs and through its investment in mAbxience Fresenius expects rapid growth in biopharmaceutical market.
Lead Product(s): Rituximab,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Novex
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Fresenius Kabi AG
Deal Size: $553.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 31, 2022
Details:
The CEP-Program is based on pre-clinical and clinical findings of Veyonda enhancing the anti-cancer effect of a number of standard chemotherapeutic agents. Receiving the ODD will speed up the Company’s commercial development plan for the important US market.
Lead Product(s): Idronoxil,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Veyonda
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
ADCETRIS is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary technology.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2022
Details:
Epizyme anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund global development and commercialization costs of tazemetostat outside of Japan.
Lead Product(s): Tazemetostat,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Tazverik
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 27, 2022
Details:
Doxil® Liposome Injection is an anthracycline topoisomerase inhibitor indicated for Ovarian Cancer, AIDS-related Kaposi's Sarcoma and Multiple Myeloma.
Lead Product(s): Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Doxil
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ayana Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Details:
In an ongoing Phase 2 clinical trial, sotigalimab is being evaluated in advanced soft tissue sarcoma in combination with doxorubicin, a chemotherapy that is currently considered standard-of-care treatment.
Lead Product(s): Sotigalimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
Celsion GmbH allows Celsion’s management to focus solely on GEN-1, its DNA-mediated IL-12 immunotherapy currently in Phase I/II development for the treatment of advanced ovarian cancer, and PLACCINE™, its nucleic acid vaccine platform.
Lead Product(s): Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: ThermoDox
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
BNL-101 is a drug-device combination comprised of doxorubicin as the active drug component together with the company's Bionaut™ microscale robots.
Lead Product(s): Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: BNL-101
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
Five-Year Update of the ECHELON-1 Clinical Trial Shows Treatment with ADCETRIS in Combination with AVD Chemotherapy Results in Superior Long-Term Outcomes when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
The study did not meet the pre-specified criteria of significance for the primary endpoint of overall survival (OS) in the intent-to-treat (ITT) population comparing lurbinectedin in combination with doxorubicin to the control arm.
Lead Product(s): Lurbinectedin,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Zepzelca
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmaMar
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
Zydus Cadila has received final approval from the USFDA to market Doxorubicin Hydrochloride Liposome Injection in the strengths of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. First approval for a complex injectable which has been developed in-house.
Lead Product(s): Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of a study that investigated Yondelis as a third-line treatment in patients with ovarian cancer.
Lead Product(s): Trabectedin,Doxorubicin Hydrochloride,Dexamethasone
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
Details:
The safety of AVB-500 has been studied in 84 subjects, including 31 healthy volunteers in a Phase 1a trial and 53 patients with PROC in a Phase 1b trial (40 in 10 mg/kg cohort, 6 in 15 mg/kg cohort, and 7 in 20 mg/kg cohort).
Lead Product(s): AVB-S6-500,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: AVB-500
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 23, 2020
Details:
iDMC is scheduled to meet to conduct the second pre-planned interim safety and efficacy analysis of the Phase III OPTIMA Study with ThermoDox® plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC).
Lead Product(s): Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: ThermoDox
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
